Form 8-K - Current report:
SEC Accession No. 0002007919-25-000003
Filing Date
2025-01-13
Accepted
2025-01-13 16:18:50
Documents
17
Period of Report
2025-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inhibrx-20250113.htm   iXBRL 8-K 42825
2 EX-4.1 exhibit41-formofwarrantoxf.htm EX-4.1 99628
3 EX-10.1 exhibit101-oxfordlsa.htm EX-10.1 394085
4 EX-99.1 exhibit991-pressreleaseoxf.htm EX-99.1 12647
8 inhibrxlogo-large.jpg GRAPHIC 961220
  Complete submission text file 0002007919-25-000003.txt   2109804

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inhibrx-20250113.xsd EX-101.SCH 1809
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inhibrx-20250113_lab.xml EX-101.LAB 23449
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inhibrx-20250113_pre.xml EX-101.PRE 13596
19 EXTRACTED XBRL INSTANCE DOCUMENT inhibrx-20250113_htm.xml XML 2929
Mailing Address 11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA CA 92037
Business Address 11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA CA 92037 (858) 795-4220
Inhibrx Biosciences, Inc. (Filer) CIK: 0002007919 (see all company filings)

EIN.: 990613523 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42031 | Film No.: 25526576
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)